Kamphorst et al. [61] demonstrated in both mouse models and samples from patients with advanced NSCLC that PD-1-targeted therapy enhances T cell responses, but this rescue requires the involvement of the CD28/B7 co-stimulatory pathway. The gene discussed is CD28; the disease is non-small cell lung carcinoma.